In Brief This Week: Sequenom; SomaLogic; Response Genetics; Cellular Dynamics; Agilent; Abbott; Veracyte; OncoGenesis | GenomeWeb

NEW YORK (GenomeWeb) – Sequenom said this week that its wholly owned subsidiary Sequenom Laboratories signed a national agreement with an unnamed insurance company for coverage of the MaterniT21 Plus non-invasive prenatal test. It is the third national coverage deal signed by Sequenom for the test. The insurer covers 13 million lives in the US and brings the total number of covered lives under agreement by the laboratory's diagnostic services to more than 140 million lives, Sequenom said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.